Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 9, 2009 - Issue 8
Submit an article Journal homepage
719
Views
94
CrossRef citations to date
0
Altmetric
Drug Profile

Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma

Paul A Meyers Vice Chair, Pediatrics, Memorial Sloan-Kettering Cancer Center, Professor of Pediatrics, Weill Cornell Medical Center, 1275 York Avenue New York, NY 10065, USA. [email protected]
Pages 1035-1049 | Published online: 10 Jan 2014

Citations (94)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (10)

Aneta Myšková, David Sýkora, Jaroslav Kuneš & Lenka Maletínská. (2023) Lipidization as a tool toward peptide therapeutics. Drug Delivery 30:1.
Read now
Bin Yang, Ana Gomes Dos Santos, Sanyogitta Puri, Annette Bak & Liping Zhou. (2022) The industrial design, translation, and development strategies for long-acting peptide delivery. Expert Opinion on Drug Delivery 19:10, pages 1233-1245.
Read now
Yuying Zhang, Qianqian Zhang, Jie Bao, Jintian Huang & Hua Zhang. (2019) Apiosporamide, A 4-hydroxy-2-pyridone Alkaloid, Induces Apoptosis Via PI3K/Akt Signaling Pathway In Osteosarcoma Cells. OncoTargets and Therapy 12, pages 8611-8620.
Read now
Lars M Wagner & Val R Adams. (2017) Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. OncoTargets and Therapy 10, pages 2097-2106.
Read now
Hui Shi, Wei-dong Mu, Bing Zhang, Tao Meng, Shou-tao Zhang & Dong-sheng Zhou. (2016) Potential role of S-adenosylmethionine in osteosarcoma development. OncoTargets and Therapy 9, pages 3653-3659.
Read now
Claudia Maria Hattinger, Marilù Fanelli, Elisa Tavanti, Serena Vella, Stefano Ferrari, Piero Picci & Massimo Serra. (2015) Advances in emerging drugs for osteosarcoma. Expert Opinion on Emerging Drugs 20:3, pages 495-514.
Read now
Winston W Huh, Daniela Egas-Bejar & Peter M Anderson. (2012) New treatment options for nonmetastatic osteosarcoma: focus on mifamurtide in adolescents. Clinical Oncology in Adolescents and Young Adults 2, pages 1-6.
Read now
Kosei Ando, Kanji Mori, Nedège Corradini, Françoise Redini & Dominique Heymann. (2011) Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opinion on Pharmacotherapy 12:2, pages 285-292.
Read now
Leo Kager, Ulrike Pötschger & Stefan Bielack. (2010) Review of mifamurtide in the treatment of patients with osteosarcoma. Therapeutics and Clinical Risk Management 6, pages 279-286.
Read now
Claudia Maria Hattinger, Michela Pasello, Stefano Ferrari, Piero Picci & Massimo Serra. (2010) Emerging drugs for high-grade osteosarcoma. Expert Opinion on Emerging Drugs 15:4, pages 615-634.
Read now

Articles from other publishers (84)

Vahab Alamdari-palangi, Khojaste Rahimi Jaberi, Mahshid Shahverdi, Yasaman Naeimzadeh, Amir Tajbakhsh, Sahar Khajeh, Vahid Razban & Jafar Fallahi. (2023) Recent advances and applications of peptide–agent conjugates for targeting tumor cells. Journal of Cancer Research and Clinical Oncology 149:16, pages 15249-15273.
Crossref
Vladislav Deigin, Natalia Linkova & Olga Volpina. (2023) Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides. International Journal of Molecular Sciences 24:17, pages 13534.
Crossref
Lauren N. Ruger, Alayna N. Hay, Jessica M. Gannon, Hannah O. Sheppard, Sheryl L. Coutermarsh-Ott, Gregory B. Daniel, Katharine R. Kierski, Brittany J. Ciepluch, Eli Vlaisavljevich & Joanne L. Tuohy. (2023) Histotripsy Ablation of Spontaneously Occurring Canine Bone Tumors . IEEE Transactions on Biomedical Engineering 70:1, pages 331-342.
Crossref
Lei Wang, Nanxi Wang, Zhibin Yan, Zhifeng Huang & Caiyun Fu. 2023. Privileged Scaffolds in Drug Discovery. Privileged Scaffolds in Drug Discovery 795 815 .
Xin Cao, Xiaojing Du, Heng Jiao, Quanlin An, Ruoxue Chen, Pengfei Fang, Jing Wang & Biao Yu. (2022) Carbohydrate-based drugs launched during 2000−2021. Acta Pharmaceutica Sinica B 12:10, pages 3783-3821.
Crossref
Shuhang Wang, Keman Cheng, Kun Chen, Chen Xu, Peiwen Ma, Guohui Dang, Yuqi Yang, Qi Lei, Huiyao Huang, Yue Yu, Yuan Fang, Qiyu Tang, Ning Jiang, Huilei Miao, Funan Liu, Xiao Zhao & Ning Li. (2022) Nanoparticle-based medicines in clinical cancer therapy. Nano Today 45, pages 101512.
Crossref
Lei Wang, Nanxi Wang, Wenping Zhang, Xurui Cheng, Zhibin Yan, Gang Shao, Xi Wang, Rui Wang & Caiyun Fu. (2022) Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy 7:1.
Crossref
Katrina M. Ingley, Alessandra Maleddu, Franel Le Grange, Craig Gerrand, Archie Bleyer, Ephia Yasmin, Jeremy Whelan & Sandra J. Strauss. (2021) Current approaches to management of bone sarcoma in adolescent and young adult patients. Pediatric Blood & Cancer 69:2.
Crossref
Baoguo Ye, Kong Qiao, Qiheng Zhao, Zhigang Jiang, Ningning Hu & Fei Wang. (2021) Tanshinone I restrains osteosarcoma progression by regulating circ_0000376/miR-432-5p/BCL2 axis. Molecular and Cellular Biochemistry 477:1, pages 1-13.
Crossref
Alannah Smrke, Yuen B. Tam, Peter M. Anderson, Robin L. Jones & Paul H. Huang. (2021) The perplexing role of immuno-oncology drugs in osteosarcoma. Journal of Bone Oncology 31, pages 100400.
Crossref
Hongfei Jiang, Xiaofei Qin, Qi Wang, Qi Xu, Jie Wang, Yudong Wu, Wujun Chen, Chao Wang, Tingting Zhang, Dongming Xing & Renshuai Zhang. (2021) Application of carbohydrates in approved small molecule drugs: A review. European Journal of Medicinal Chemistry 223, pages 113633.
Crossref
Samo Guzelj, Sanja Nabergoj, Martina Gobec, Stane Pajk, Veronika Klančič, Bram Slütter, Ruža Frkanec, Adela Štimac, Primož Šket, Janez Plavec, Irena Mlinarič-Raščan & Žiga Jakopin. (2021) Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their In Vivo Adjuvant Activity . Journal of Medicinal Chemistry 64:11, pages 7809-7838.
Crossref
Carmen Paus, Robbert van der Voort & Alessandra Cambi. (2021) Nanomedicine in cancer therapy: promises and hurdles of polymeric nanoparticles. Exploration of Medicine.
Crossref
Svetlana V. Guryanova & Rahim M. Khaitov. (2021) Strategies for Using Muramyl Peptides - Modulators of Innate Immunity of Bacterial Origin - in Medicine. Frontiers in Immunology 12.
Crossref
Peng Zhang & Jun Li. (2021) Down-regulation of circular RNA hsa_circ_0007534 suppresses cell growth by regulating miR-219a-5p/SOX5 axis in osteosarcoma. Journal of Bone Oncology 27, pages 100349.
Crossref
Chenyang Zhang, Liang Yan, Xin Wang, Shuang Zhu, Chunying Chen, Zhanjun Gu & Yuliang Zhao. (2020) Progress, challenges, and future of nanomedicine. Nano Today 35, pages 101008.
Crossref
Bram Priem, Mandy M.T. van Leent, Abraham J.P. Teunissen, Alexandros Marios Sofias, Vera P. Mourits, Lisa Willemsen, Emma D. Klein, Roderick S. Oosterwijk, Anu E. Meerwaldt, Jazz Munitz, Geoffrey Prévot, Anna Vera Verschuur, Sheqouia A. Nauta, Esther M. van Leeuwen, Elizabeth L. Fisher, Karen A.M. de Jong, Yiming Zhao, Yohana C. Toner, Georgios Soultanidis, Claudia Calcagno, Paul H.H. Bomans, Heiner Friedrich, Nico Sommerdijk, Thomas Reiner, Raphaël Duivenvoorden, Eva Zupančič, Julie S. Di Martino, Ewelina Kluza, Mohammad Rashidian, Hidde L. Ploegh, Rick M. Dijkhuizen, Sjoerd Hak, Carlos Pérez-Medina, Jose Javier Bravo-Cordero, Menno P.J. de Winther, Leo A.B. Joosten, Andrea van Elsas, Zahi A. Fayad, Alexander Rialdi, Denis Torre, Ernesto Guccione, Jordi Ochando, Mihai G. Netea, Arjan W. Griffioen & Willem J.M. Mulder. (2020) Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition. Cell 183:3, pages 786-801.e19.
Crossref
Ingrid Lilienthal & Nikolas Herold. (2020) Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. International Journal of Molecular Sciences 21:18, pages 6885.
Crossref
Isabelle Corre, Franck Verrecchia, Vincent Crenn, Francoise Redini & Valérie Trichet. (2020) The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem. Cells 9:4, pages 976.
Crossref
Zhenhua Zhou, Yan Li, Muyu Kuang, Xudong Wang, Qi Jia, Jiashi Cao, Jingjing Hu, Sujia Wu, Zhiwei Wang & Jianru Xiao. (2020) The CD24+ cell subset promotes invasion and metastasis in human osteosarcoma. EBioMedicine 51, pages 102598.
Crossref
Massimo Serra & Claudia Maria Hattinger. 2020. Diagnosis of Musculoskeletal Tumors and Tumor-like Conditions. Diagnosis of Musculoskeletal Tumors and Tumor-like Conditions 213 215 .
Zhiqiang Li, Renjie Xu, Xiangxin Zhang, Jun Shen, Guangxiang Chen, Tianming Zou & Xiao Yu. (2019) Interleukin‑22 modulates cisplatin sensitivity of osteosarcoma cells by regulating the STAT3 signaling pathway. Experimental and Therapeutic Medicine.
Crossref
Lidia Tarone, Giuseppina Barutello, Selina Iussich, Davide Giacobino, Elena Quaglino, Paolo Buracco, Federica Cavallo & Federica Riccardo. (2019) Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy. Cancer Immunology, Immunotherapy 68:11, pages 1839-1853.
Crossref
Leila Martinez Beltrán, Daniel Ozaeta Eidelman & Natalia Lucía González Suárez. (2019) Caracterización de los niños con osteosarcoma no metastásico quienes recibieron tratamiento con mifamurtida en dos instituciones de Bogotá (Colombia) entre 2014 y 2017. Universitas Médica 60:4, pages 1-8.
Crossref
Sanja Nabergoj, Irena Mlinarič‐Raščan & Žiga Jakopin. (2018) Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy. Medicinal Research Reviews 39:5, pages 1447-1484.
Crossref
Rosana Ribić, Ranko Stojković, Lidija Milković, Mariastefania Antica, Marko Cigler & Srđanka Tomić. (2019) Design, synthesis and biological evaluation of immunostimulating mannosylated desmuramyl peptides. Beilstein Journal of Organic Chemistry 15, pages 1805-1814.
Crossref
Hangzhan Ma, Nicole A. Seebacher, Francis J. Hornicek & Zhenfeng Duan. (2019) Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma. EBioMedicine 39, pages 182-193.
Crossref
Gopalakrishna Pillai. 2019. Applications of Targeted Nano Drugs and Delivery Systems. Applications of Targeted Nano Drugs and Delivery Systems 221 256 .
Mary Frances Wedekind, Nicholas L. Denton, Chun-Yu Chen & Timothy P. Cripe. (2018) Pediatric Cancer Immunotherapy: Opportunities and Challenges. Pediatric Drugs 20:5, pages 395-408.
Crossref
Roger Gilabert-Oriol, Gemma Ryan, Ada Leung, Natalie Firmino, Kevin Bennewith & Marcel Bally. (2018) Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response. International Journal of Molecular Sciences 19:10, pages 2922.
Crossref
Khaled Greish, Aanchal Mathur, Moiz Bakhiet & Sebastien Taurin. (2018) Nanomedicine: is it lost in translation?. Therapeutic Delivery 9:4, pages 269-285.
Crossref
Hangzhan Ma, Xiaoyang Li, Jinglu Wang, Francis J. Hornicek, Cassandra C. Garbutt, Xu Chang & Zhenfeng Duan. (2018) Expression and Clinical Implication of Autophagy-Associated Protein p62 in Osteosarcoma. Oncology 95:1, pages 52-60.
Crossref
Kun Han, Yan Zhou, Kuo‑Fu Tseng, Haiyan Hu, Kunpeng Li, Yaling Wang, Zhihua Gan, Shuchen Lin, Yongning Sun & Daliu Min. (2017) PAK5 overexpression is associated with lung metastasis in osteosarcoma. Oncology Letters.
Crossref
Katarzyna Zabielska-Koczywąs & Roman Lechowski. (2017) The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats. Molecules 22:12, pages 2167.
Crossref
Yan Zhang, Ying Liu, Jilong Zou, Lixin Yan, Wei Du, Yafeng Zhang, Hanliang Sun, Peng Lu, Shuo Geng, Rui Gu, Hongyue Zhang & Zhenggang Bi. (2017) Tetrahydrocurcumin induces mesenchymal-epithelial transition and suppresses angiogenesis by targeting HIF-1α and autophagy in human osteosarcoma. Oncotarget 8:53, pages 91134-91149.
Crossref
Jenna S. Bleloch, Reyna D. Ballim, Serah Kimani, Jeannette Parkes, Eugenio Panieri, Tarryn Willmer & Sharon Prince. (2017) Managing sarcoma: where have we come from and where are we going?. Therapeutic Advances in Medical Oncology 9:10, pages 637-659.
Crossref
Zhenhua Zhou, Yan Li, Xu Yan, Xudong Wang, Cheng Yang, Haifeng Wei, Xinghai Yang & Jianru Xiao. (2017) Does rarity mean imparity? Biological characteristics of osteosarcoma cells originating from the spine. Journal of Cancer Research and Clinical Oncology 143:10, pages 1959-1969.
Crossref
Rincy Jimmy, Cindy Stern, Karolina Lisy & Sarahlouise White. (2017) Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review. JBI Database of Systematic Reviews and Implementation Reports 15:8, pages 2113-2152.
Crossref
Zhen Liu & Yan Song. (2017) Characterizing biomarkers in osteosarcoma metastasis based on an ego-network. Biotechnology Letters 39:6, pages 841-848.
Crossref
Jian Yang, Weichun Guo, Lu Wang, Ling Yu, Hongjun Mei, Shuo Fang, Anyuan Chen, Yang Liu, Kezhou Xia & Gaiwei Liu. (2017) Notch signaling is important for epithelial-mesenchymal transition induced by low concentrations of doxorubicin in osteosarcoma cell lines. Oncology Letters 13:4, pages 2260-2268.
Crossref
Lankai Yi, Meixiu Liu & Zhiliang Tang. (2017) MicroRNA-130a inhibits growth and metastasis of osteosarcoma cells by directly targeting ZEB1. Molecular Medicine Reports 16:3, pages 3606-3612.
Crossref
Leo Kager, Gevorg Tamamyan & Stefan Bielack. (2017) Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncology 13:4, pages 357-368.
Crossref
R. Braster, M. Bögels, R.H.J. Beelen & M. van Egmond. (2017) The delicate balance of macrophages in colorectal cancer; their role in tumour development and therapeutic potential. Immunobiology 222:1, pages 21-30.
Crossref
Peter M. Anderson. 2017. Immunotherapy. Immunotherapy 127 140 .
Ren-zeng Li & Li-min Wang. (2016) RETRACTED ARTICLE: Decreased microRNA-452 expression and its prognostic significance in human osteosarcoma. World Journal of Surgical Oncology 14:1.
Crossref
Jian Yang, Weichun Guo, Lu Wang, Ling Yu, Hongjun Mei, Shuo Fang, Peng Ji, Yang Liu, Gaiwei Liu & Qi Song. (2016) Cisplatin-resistant osteosarcoma cells possess cancer stem cell properties in a mouse model. Oncology Letters 12:4, pages 2599-2605.
Crossref
Yan Gao, Yunfei Liao, Jacson K. Shen, Yong Feng, Edwin Choy, Gregory Cote, David Harmon, Henry J. Mankin, Francis J. Hornicek & Zhenfeng Duan. (2016) Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray. Journal of Orthopaedic Research 34:9, pages 1606-1612.
Crossref
James E. Talmadge. (2016) Natural product derived immune-regulatory agents. International Immunopharmacology 37, pages 5-15.
Crossref
Riccardo Di Fiore, Rosa Drago-Ferrante, Francesca Pentimalli, Domenico Di Marzo, Iris Maria Forte, Daniela Carlisi, Anna De Blasio, Giovanni Tesoriere, Antonio Giordano & Renza Vento. (2016) Let-7d miRNA Shows Both Antioncogenic and Oncogenic Functions in Osteosarcoma-Derived 3AB-OS Cancer Stem Cells. Journal of Cellular Physiology 231:8, pages 1832-1841.
Crossref
Wei Li, Peng Xie & Wen-hui Ruan. (2016) Overexpression of lncRNA UCA1 promotes osteosarcoma progression and correlates with poor prognosis. Journal of Bone Oncology 5:2, pages 80-85.
Crossref
Lisa Bregoli, Dania Movia, James D. Gavigan-Imedio, Joanne Lysaght, John Reynolds & Adriele Prina-Mello. (2016) Nanomedicine applied to translational oncology: A future perspective on cancer treatment. Nanomedicine: Nanotechnology, Biology and Medicine 12:1, pages 81-103.
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs 1032 .
Zhiyan Xiao, Susan L. Morris‐Natschke & Kuo‐Hsiung Lee. (2015) Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates. Medicinal Research Reviews 36:1, pages 32-91.
Crossref
Xin Li, Jiguang Tian, Qiyu Bo, Ka Li, Hongliang Wang, Ting Liu & Jianmin Li. (2015) Targeting DNA-PKcs increased anticancer drug sensitivity by suppressing DNA damage repair in osteosarcoma cell line MG63. Tumor Biology 36:12, pages 9365-9372.
Crossref
Yan Gao, Yong Feng, Jacson K. Shen, Min Lin, Edwin Choy, Gregory M. Cote, David C. Harmon, Henry J. Mankin, Francis J. Hornicek & Zhenfeng Duan. (2015) CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma. Scientific Reports 5:1.
Crossref
Shun-Fa Yang, Wei-Jiunn Lee, Peng Tan, Chih-Hsin Tang, Michael Hsiao, Feng-Koo Hsieh & Ming-Hsien Chien. (2014) Upregulation of miR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of matrix metalloproteinase-2 and subsequent metastatic ability in human osteosarcomas. Oncotarget 6:5, pages 2736-2753.
Crossref
Yuanlong Xie. (2015) The Prognostic Significance of Src and p-Src Expression in Patients with Osteosarcoma. Medical Science Monitor 21, pages 638-645.
Crossref
LeLe Aung, Aung Soe Tin, Thuan Chong Quah & Robert W Pho. (2014) Osteogenic Sarcoma in Children and Young Adults. Annals of the Academy of Medicine, Singapore 43:6, pages 305-313.
Crossref
Hsiao-Chi Tsai, Hong-Lin Su, Chun-Yin Huang, Yi-Chin Fong, Chin-Jung Hsu & Chih-Hsin Tang. (2014) CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d. Oncotarget 5:11, pages 3800-3812.
Crossref
Jiguang Tian, Xin Li, Meng Si, Ting Liu & Jianmin Li. (2014) CD271+ Osteosarcoma Cells Display Stem-Like Properties. PLoS ONE 9:6, pages e98549.
Crossref
Karthik Venkatakrishnan, Yi Liu, Dennis Noe, Jaime Mertz, Michael Bargfrede, Thomas Marbury, Kambiz Farbakhsh, Cristina Oliva & Ashley Milton. (2014) Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment. British Journal of Clinical Pharmacology 77:6, pages 998-1010.
Crossref
Karthik Venkatakrishnan, Yi Liu, Dennis Noe, Jaime Mertz, Michael Bargfrede, Thomas Marbury, Kambiz Farbakhsh, Cristina Oliva & Ashley Milton. (2014) Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment. British Journal of Clinical Pharmacology 77:6, pages 986-997.
Crossref
Marika Sciandra, Maria Teresa Marino, Maria Cristina Manara, Clara Guerzoni, Maria Grano, Angela Oranger, Enrico Lucarelli, Pier‐Luigi Lollini, Barbara Dozza, Loredana Pratelli, Maria Flavia Di Renzo, Mario Paolo Colombo, Piero Picci & Katia Scotlandi. (2014) CD99 Drives Terminal Differentiation of Osteosarcoma Cells by Acting as a Spatial Regulator of ERK 1/2. Journal of Bone and Mineral Research 29:5, pages 1295-1309.
Crossref
Mingkun Fu, Wei Xu, Qing Lu, Guoyu Pan & Csanad Varga. (2014) Evaluation and optimization of high-performance liquid chromatography coupled with high-resolution mass spectrometry for phospholipid quantitation. Rapid Communications in Mass Spectrometry 28:7, pages 811-821.
Crossref
Swagatika Panda, Kanaram Choudhary, Gunjan Srivastava, Subrat Kumar Padhiary, Kanika Singh Dhull & Dipti Sanghavi. (2014) An Indian perspective on gnathic osteosarcoma: A comprehensive literature review of the last three decades. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology 26:2, pages 198-206.
Crossref
P.M. Anderson, P. Meyers, E. Kleinerman, K. Venkatakrishnan, D.P. Hughes, C. Herzog, W. Huh, R. Sutphin, Y.M. Vyas, V. Shen, A. Warwick, N. Yeager, C. Oliva, B. Wang, Y. Liu & A. Chou. (2013) Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatric Blood & Cancer 61:2, pages 238-244.
Crossref
Rincy Jimmy, Sarahlouise White & Karolina Lisy. (2014) Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports 12:11, pages 61-73.
Crossref
Mark S. Butler, Avril A. B. Robertson & Matthew A. Cooper. (2014) Natural product and natural product derived drugs in clinical trials. Nat. Prod. Rep. 31:11, pages 1612-1661.
Crossref
Nan Zheng, Wenlei Jiang, Robert Lionberger & Lawrence X. Yu. 2014. FDA Bioequivalence Standards. FDA Bioequivalence Standards 275 296 .
Xia Zhang, Anindita Sarangi, Dai-Tze Wu, Jaya Kanduri & Monica J Roth. (2013) Gene delivery in a mouse xenograft of a retargeted retrovirus to a solid 143B osteosarcoma. Virology Journal 10:1.
Crossref
Gábor Mezo. 2013. Amino Acids, Peptides and Proteins. Amino Acids, Peptides and Proteins 203 252 .
HUI-JYE CHEN, CHUNG-MING LIN, CHAO-YING LEE, NAI-CHEN SHIH, SHU-FEN PENG, MINORU TSUZUKI, SAKAE AMAGAYA, WEN-WEN HUANG & JAI-SING YANG. (2013) Kaempferol suppresses cell metastasis via inhibition of the ERK-p38-JNK and AP-1 signaling pathways in U-2 OS human osteosarcoma cells. Oncology Reports 30:2, pages 925-932.
Crossref
Jyothi Thundimadathil. (2012) Cancer Treatment Using Peptides: Current Therapies and Future Prospects. Journal of Amino Acids 2012, pages 1-13.
Crossref
Annemiek M van Maldegem, Aparna Bhosale, Hans J Gelderblom, Pancras CW Hogendoorn & Andrew B Hassan. (2012) Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment. Clinical Sarcoma Research 2:1.
Crossref
Liliana Endo-Munoz, Andreas Evdokiou & Nicholas A. Saunders. (2012) The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1826:2, pages 434-442.
Crossref
ANNE-SOPHIE HÖNICKE, STEPHAN ALBRECHT ENDER & JÜRGEN RADONS. (2012) Combined administration of EGCG and IL-1 receptor antagonist efficiently downregulates IL-1-induced tumorigenic factors in U-2 OS human osteosarcoma cells. International Journal of Oncology 41:2, pages 753-758.
Crossref
T.S. Osborne & C. Khanna. (2012) A Review of the Association between Osteosarcoma Metastasis and Protein Translation. Journal of Comparative Pathology 146:2-3, pages 132-142.
Crossref
R Grant Rowe & Rashmi Chugh. (2011) Clinical trials of systemic therapy in osteosarcoma and Ewing’s sarcoma: past, present and future. Clinical Investigation 1:10, pages 1421-1443.
Crossref
Tanasa S. Osborne, Ling Ren, John H. Healey, Lauren Q. Shapiro, Alexander J. Chou, Richard G. Gorlick, Stephen M. Hewitt & Chand Khanna. (2011) Evaluation of eIF4E Expression in an Osteosarcoma-Specific Tissue Microarray. Journal of Pediatric Hematology/Oncology 33:7, pages 524-528.
Crossref
Yao Ma, Nan Zhao & Gang Liu. (2011) Conjugate (MTC-220) of Muramyl Dipeptide Analogue and Paclitaxel Prevents Both Tumor Growth and Metastasis in Mice. Journal of Medicinal Chemistry 54:8, pages 2767-2777.
Crossref
James E. Talmadge. 2011. Principles of Immunopharmacology. Principles of Immunopharmacology 373 410 .
James E. Frampton. (2010) Mifamurtide. Pediatric Drugs 12:3, pages 141-153.
Crossref
Amit S. Adhikari, Neeraj Agarwal, Byron M. Wood, Constance Porretta, Bernardo Ruiz, Radhika R. Pochampally & Tomoo Iwakuma. (2010) CD117 and Stro-1 Identify Osteosarcoma Tumor-Initiating Cells Associated with Metastasis and Drug Resistance. Cancer Research 70:11, pages 4602-4612.
Crossref
C.S. Siller & I.J. Lewis. (2010) Update and review of the management of bone tumours. Paediatrics and Child Health 20:3, pages 103-108.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.